Article
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS.
Blood advances - 10 Nov 2020
Stengel Anna, Shahswar Rabia, Haferlach Torsten, Walter Wencke, Hutter Stephan, Meggendorfer Manja, Kern Wolfgang, Haferlach Claudia
Abstract excerpt
Fusion transcripts are frequent genetic abnormalities in myeloid malignancies and are often the basis for risk stratification, minimal residual disease (MRD) monitoring, and targeted therapy. We comprehensively analyzed the fusion transcript landscape in 572 acute myeloid leukemia (AML) and 630 myelodysplastic syndrome (MDS) patients by whole transcriptome sequencing (WTS). Totally, 274 fusion events (131 unique...
Topics
Join the communities discussing this publication.
